DALLAS, TX, April 25, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals Inc. (NASDAQ:MGRX) ("Mangoceuticals" or "MGRX"), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx, is pleased to announce that it has entered into an Intellectual Property Purchase Agreement to acquire all intellectual property, product formulations, know-how, distribution, supplier relationships and related assets of Smokeless Technology Corp. ("Smokeless Tech"), a Canadian-based pouch innovation company specializing in stimulant and functional pouches. This acquisition marks a strategic expansion into the

Dallas, TX, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling men's health and wellness products via a secure telemedicine platform, today announced the acquisition of patent number WO 2023/086647 PCT/US2022/049857, for mushroom-derived compositions and methods of treatment. This new addition to MangoRx's intellectual property portfolio highlights the Company's commitment to innovative solutions that support holistic health and wellness. The acquired patent encompasses nutraceutical compositions derived from functional mushrooms, including well-known varieties such as Cordyceps sinensi

Dallas, Texas, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling a variety of men's health and wellness products in the area of erectile dysfunction (ED), hair growth, weight loss, and hormone replacement therapies, today announced its financial results for the three and six months ending June 30, 2024, showing a significant growth in both shareholder's equity and gross revenues. During the six months ending June 30, 2024, MangoRx's shareholder equity increased to $13,829,445, compared to $774,754 as of December 31, 2023, reflecting an increase of 1,685%, or $13,054,691. A substantial

DALLAS, TX, April 25, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals Inc. (NASDAQ:MGRX) ("Mangoceuticals" or "MGRX"), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx, is pleased to announce that it has entered into an Intellectual Property Purchase Agreement to acquire all intellectual property, product formulations, know-how, distribution, supplier relationships and related assets of Smokeless Technology Corp. ("Smokeless Tech"), a Canadian-based pouch innovation company specializing in stimulant and functional pouches. This acquisition marks a strategic expansion into the

Diabetinol® is a clinically supported and patented plant-based nutraceutical product targeting the pre-diabetic and weight loss marketplace DALLAS, TX, March 25, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("Mangoceuticals" or the "Company"), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx, today announced that it has entered into a Master Distribution Agreement (the "Agreement") to secure the exclusive licensing and distribution rights for Diabetinol® within the United States and Canada. Diabetinol® is a plant-based nutraceutical clinically supporte

Dallas, Texas, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("Mangoceuticals" or the "Company"), a company focused on developing, marketing, and selling a variety of men's wellness products via a secure telemedicine platform under the brand MangoRx, proudly announces the official launch of PeachesRx, an innovative women's health and wellness brand focused on providing cutting-edge, convenient treatments tailored to women's unique health needs. These new and innovative women's health and wellness products will be made available via a secure telemedicine platform located at www.PeachesRx.com. PeachesRx will debut with a strong focus on compounded GLP-1 receptor agoni

Dallas, Texas, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("Mangoceuticals" or the "Company"), a company focused on developing, marketing, and selling a variety of innovative health solutions today announced that it is advancing its research into respiratory illness prevention technologies by focusing on finding a practical, everyday solution to combat avian influenza viruses (H5N1), specifically within the poultry industry. The Company has engaged Vipragen Biosciences, an AAALAC-accredited preclinical Contract Research Organization (CRO) based in Mysuru, India ("Vipragen"), to conduct independent efficacy studies aimed at developing an antiviral solution for res

Dallas, Texas, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("Mangoceuticals" or the "Company"), a company focused on developing, marketing, and selling a variety of men's wellness products and services via a secure telemedicine platform, today announced significant progress in its ongoing H1N1 efficacy study conducted by Vipragen Biosciences ("Vipragen"), an AAALAC-accredited preclinical CRO in Mysuru, India, on its patented respiratory illness prevention technology in collaboration with Intramont Technologies, Inc. ("Intramont"). Building on strong preliminary results, the Company is advancing to the next stage of research while also engaging Vipragen to structur

Dallas, TX & Quebec, Canada, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX), a company focused on developing, marketing, and selling a variety of men's wellness products and services via a secure telemedicine platform, is pleased to announce that it has entered into an exclusive Master Distribution Agreement with Propre Energie, Inc., the developer of skincare brand Dermytol®, a clinically proven treatment designed to improve skin tone and reduce hyperpigmentation. Dermytol® is an advanced, plant-based formula developed to address dark spots, uneven skin tone, acne scars, and other pigmentation concerns. Unlike traditional skin treatments that may cause irritation or

Dallas, TX, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling men's health and wellness products via a secure telemedicine platform, today announced the acquisition of patent number WO 2023/086647 PCT/US2022/049857, for mushroom-derived compositions and methods of treatment. This new addition to MangoRx's intellectual property portfolio highlights the Company's commitment to innovative solutions that support holistic health and wellness. The acquired patent encompasses nutraceutical compositions derived from functional mushrooms, including well-known varieties such as Cordyceps sinensi

DALLAS, TX, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling men's health and wellness products via a secure telemedicine platform, today announced that it has launched an investigation into potential stock manipulation related to and following its recent reverse stock split, which was effective as of October 16, 2024. This decision follows a comprehensive review of highly irregular trading patterns and an unprecedented increase in the number of shareholder accounts, factors that collectively raise concerns about potential stock manipulation. This investigation also follows a recent r

Dallas, Texas, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling men's health and wellness products via a secure telemedicine platform, today announced that the Company received a letter on October 30, 2024 from The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company has regained full compliance with the minimum bid price for continued listing on the Nasdaq pursuant to Nasdaq Listing Rule 5550(a)(2) ("Minimum Bid Price Requirement"). As indicated in the letter, Nasdaq determined that for 10 consecutive business days, the closing bid price of the Company's common stock was at

Dallas, Texas, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling men's health and wellness products via a secure telemedicine platform, today announced that its Board of Directors has initiated a process to evaluate potential strategic alternatives with the intent to unlock and maximize shareholder value, including but not limited to potential mergers, acquisitions, divestitures and business combinations, acquisitions of businesses, entry into new lines of business, business expansions, joint ventures, and other key strategic transactions outside the ordinary course of the Company's cur